首页> 美国卫生研究院文献>Cell Death Disease >LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint
【2h】

LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint

机译:LncRNA SNHG14 / miR-5590-3p / ZEB1阳性反馈环通过调节PD-1 / PD-L1检查点促进弥漫性大B细胞淋巴瘤进展和免疫逃逸

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diffuse large B cell lymphoma (DLBCL) is the commonest disorder derived from the B-lymphocytes. Inhibiting the immune checkpoint through naturalizing programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) is proved to be a successful therapeutic regime for lymphoma. Long non-coding RNAs (lncRNAs) are unceasingly reported to be promising biological targets for the cancer therapies. This study planned to explore the regulation of small nucleolar RNA host gene 14 (SNHG14) on DLBCL. SNHG14 level in DLBCL samples and cell lines was analyzed by GEPIA bioinformatics tool and RT-qPCR. Biological functions of SNHG14 in DLBCL were detected by CCK-8, colony formation, and transwell invasion assays. Molecular interaction was determined by RNA immunoprecipitation (RIP) and luciferase reporter assays. MiR-5590-3p-related pathway was identified through KEGG pathway analysis applying DAVID6.8 online bioinformatics tool. Effect of SNHG14 on CD8+ T cells was detected by flow cytometry. Results depicted that SNHG14 was upregulated in DLBCL and its depletion retarded proliferation, migration and epithelial-to-mesenchymal transition (EMT). Mechanistically, SNHG14 sponged miR-5590-3p to upregulate Zinc finger E-box binding homeobox 1 (ZEB1), and ZEB1 transcriptionally activated SNHG14 and PD-L1 to promote the immune evasion of DLBCL cells. In conclusion, we firstly showed that SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint, indicating that targeting SNHG14 was a potential approach to improve the efficacy of immunotherapy in DLBCL.
机译:弥漫性大B细胞淋巴瘤(DLBCL)是源自B淋巴细胞的最常见疾病。通过使程序性死亡1(PD-1)和程序性死亡配体1(PD-L1)自然化来抑制免疫检查点被证明是淋巴瘤的成功治疗方案。长的非编码RNA(lncRNA)不断报道是癌症治疗的有希望的生物学目标。这项研究计划探索对DLBCL的小核仁RNA宿主基因14(SNHG14)的调控。通过GEPIA生物信息学工具和RT-qPCR分析DLBCL样品和细胞系中的SNHG14水平。 SNHG14在DLBCL中的生物学功能通过CCK-8,集落形成和transwell入侵检测来检测。分子相互作用是通过RNA免疫沉淀(RIP)和萤光素酶报告基因测定的。通过使用DAVID6.8在线生物信息学工具的KEGG途径分析,确定了与MiR-5590-3p相关的途径。通过流式细胞术检测了SNHG14对CD8 + T细胞的作用。结果表明SNHG14在DLBCL中被上调,其耗竭可抑制增殖,迁移和上皮-间充质转化(EMT)。从机制上讲,SNHG14使miR-5590-3p上调了锌指E-box结合同源盒1(ZEB1)的水平,ZEB1转录激活SNHG14和PD-L1以促进DLBCL细胞的免疫逃逸。总之,我们首先表明SNHG14 / miR-5590-3p / ZEB1阳性反馈环通过调节PD-1 / PD-L1检查点来促进弥漫性大B细胞淋巴瘤进展和免疫逃逸,这表明靶向SNHG14是改善疾病的一种潜在方法。 DLBCL免疫疗法的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号